Gold Line Resources Ltd
Change company Symbol lookup
Select an option...
TLLZF Gold Line Resources Ltd
DWAC Digital World Acquisition Corp
TMP Tompkins Financial Corp
CCF Chase Corp
CHKP Check Point Software Technologies Ltd
GGXXF Ggx Gold Corp
ICE Intercontinental Exchange Inc
AICAF Air China Ltd
LGF.A Lions Gate Entertainment Corp
COMM CommScope Holding Company Inc
Go


Based in Canada
Company profile

Gold Line Resources Ltd. is a Canada-based company. The Company’s principal business activity is the acquisition and exploration of mineral property interests, particularly in Sweden and Finland. It holds a portfolio of advanced and early stage gold exploration properties in Sweden and Finland, including the Oijarvi Project, which includes the Kylmakangas deposit, in the Oijarvi Greenstone Belt of Finland; the Solvik Gold Project, located in Sweden, the Kankberg Norra property in the Skelleftea Belt , and the Langtjarn property (comprised of the Stojuktan North and Storjuktan South licences), the Blabarliden property, and the Paubacken property, all located within the Gold Line Mineral Belt, in Sweden. The Langtjarn property is a 22,336-hectare license package located at the northern end of the Gold Line Mineral Belt of North Central Sweden. The Blabarliden property consists of a 3,806-hectare license package. The Paubacken property consist of 16,724-hectare licensed package.

Closing Price
$0.1191
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.1191
Day's Low
0.1191
Volume
900

AbbVie Inc. Stock Falls Wednesday, Still Outperforms Market

4:33 pm ET November 16, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) slid 0.76% to $151.87 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.83% to 3,958.79 and Dow Jones Industrial Average falling 0.12% to 33,553.83. The stock's fall snapped a four-day winning streak. AbbVie Inc. closed $24.04 below its 52-week high ($175.91), which the company reached on April 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Pfizer Inc. (PFE) fell 1.07% to $48.05, Eli Lilly & Co. (LLY) rose 0.85% to $352.93, and AstraZeneca PLC ADR (AZN.LN) fell 0.23% to $63.80. Trading volume (7.2 M) eclipsed its 50-day average volume of 5.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 16, 2022.

	

(END) Dow Jones Newswires

November 16, 2022 16:33 ET (21:33 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.